Biopharma IPOs Start To Gear Up For 2013 After A Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.
You may also be interested in...
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the second day of the 2014 J.P. Morgan health care conference, including news from ZS Pharma, Aisling Capital, Astellas, and Moderna.
Once wary of the IPO market, the antiviral drug developer looks to public investors as it prepares to fund a Phase III trial for a well-regarded but unpartnered cytomegalovirus drug.
Plus news on recent financings by Tesaro, Ablynx, Spring Bank Pharmaceuticals and Daiichi Sankyo.